Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead 1Q Sales Slip 4% Due to Lower Veklury Sales | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Gilead 1Q Sales Slip 4% Due to Lower Veklury Sales

Biktarvy sales up 24% and Oncology revenue increased 59% in the quarter, driven by Trodelvy and Cell Therapy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
1Q Revenue: $6.4 billion (-4%)
1Q Earnings: $985 million (earnings were $12 million 1Q22)
Comments: Results in the quarter were impacted by lower Veklury (remdesivir) sales, partially offset by increased sales in HIV and Oncology. HIV product sales increased 13% to $4.2 billion in the quarter. Biktarvy sales increased 24% mostly reflecting higher demand. Descovy sales increased 20% primarily driven by higher demand and favorable pricing dynamics. Liver Disease portfolio sales, which includes chronic hepatitis C virus (HCV), chronic hepatitis B virus (HBV) and chronic hepatitis delta virus (HDV), increased 6% to $675 million in the first quarter. Cell Therapy product sales increased 64% to $448 million in the quarter, with Yescarta sales up 70% to $359 million, primarily driven by increased demand in relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Tecartus sales increased 40% to $89 million in quarter, primarily driven by increased demand in R/R mantle cell lymphoma and R/R adult acute lymphoblastic leukemia (ALL).

A $2.7 billion in-process research and development (IPR&D) impairment recorded in the first quarter of 2022, which did not repeat in 2023, partially offset by higher operating expenses, including higher acquired IPR&D expense and lower revenues in 2023.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters